Racial differences in treatment preferences among lupus patients: a two-site study

To identify the demographic, clinical and psychosocial characteristics associated with racial differences in willingness to receive cyclophosphamide (CYC) or participate in a research clinical trial (RCT) among patients with systemic lupus erythematosus (SLE). Data from 163 African-American (AA) and...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2014-09, Vol.32 (5), p.680-688
Main Authors: Vina, Ernest R, Utset, Tammy O, Hannon, Michael J, Masi, Christopher M, Roberts, Nicole, Kwoh, C Kent
Format: Article
Language:English
Subjects:
Adult
African Americans - psychology
Chi-Square Distribution
Chicago
Clinical Trials as Topic - methods
Cyclophosphamide - therapeutic use
European Continental Ancestry Group - psychology
Female
Health Knowledge, Attitudes, Practice - ethnology
Humans
Immunosuppressive Agents - therapeutic use
Logistic Models
Lupus Erythematosus, Systemic - diagnosis
Lupus Erythematosus, Systemic - ethnology
Lupus Erythematosus, Systemic - psychology
Lupus Erythematosus, Systemic - therapy
Male
Middle Aged
Odds Ratio
Patient Preference - ethnology
Patient Selection
Pennsylvania
Research Subjects - psychology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To identify the demographic, clinical and psychosocial characteristics associated with racial differences in willingness to receive cyclophosphamide (CYC) or participate in a research clinical trial (RCT) among patients with systemic lupus erythematosus (SLE). Data from 163 African-American (AA) and 180 white (WH) SLE patients were evaluated. Structured interviews and chart reviews were conducted to determine treatment preferences in hypothetical situations and identify variables that may affect preferences. Logistic regression models were performed to evaluate the relationship between patient preferences and race, adjusted for patient characteristics. Among patients who had never received CYC (n=293), 62.9% AAs compared to 87.6% WHs were willing to receive the medication (p
ISSN:0392-856X